COPENHAGEN — Pharmaceutical behemoth Novo Nordisk declared a new era of affordability this week, announcing it would slash the list prices of its popular GLP-1 drugs, including Ozempic and Wegovy, by up to 50% for insured U.S. patients. The move, hailed by industry analysts as a 'bold step towards merely exorbitant pricing,' aims to make the life-changing medications more accessible to those with high-deductible health plans.

“We listened to the American people, who told us, in no uncertain terms, that our prices were, and I quote, ‘absolutely bonkers,’” stated CEO Lars Fruergaard Jørgensen in a press release. “This reduction ensures that patients will now only have to choose between their life-saving medication and, say, a mid-sized sedan, instead of a small house.”

Experts suggest the decision was purely altruistic, entirely unrelated to the drugs' impending patent expirations, the growing public outcry over drug costs, or the looming threat of government price negotiation. “It’s a testament to their corporate compassion,” said Dr. Evelyn Finch, a healthcare economist from the Institute for Profitable Philanthropy. “They’re practically giving these drugs away, provided you have excellent insurance and a healthy tolerance for still paying thousands.”

The company confirmed that uninsured patients, or those with less comprehensive plans, would continue to enjoy the full, unadulterated experience of paying full price.